glutathion-s-transferase-mangel Glutathione S-transferase: A keystone in Parkinson's disease pathogenesis and therapy Glutathione S-Transferase | Oxford Biomedical
Description
( B ) Ppargc1a mRNA levels in AC16 cells treated with 50 M rosiglitazone (PPAR agonist), 50 M WY-14643 (PPAR agonist), a combination of rosiglitazone and WY-14643, or a combination of rosiglitazone, WY-14643, and 10 M MK886 (PPAR antagonist) ( B
Volume ranging from 20 to 60 mL can be infiltrated per sides of the cheeks (Figures 2, 3, 4)
This is one of the theoretical advantages of the dual GIP/GLP-1 approach over the amylin/GLP-1 approach
References National Center for Biotechnology Information
